Compare Boston Scientific Corporation (BSX) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Hyatt Hotels Corporation — how do they compare? Boston Scientific Corporation trades at $51.12 (market cap $71.46B), while Hyatt Hotels Corporation trades at $172.22 (market cap $16.03B). The key difference: Boston Scientific Corporation is far larger — about 4.5× Hyatt Hotels Corporation's market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | H | |
|---|---|---|
Market Cap | $71.46B | $16.03B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $202.09 |
52-Week Low | $42.63 | $135.42 |
Enterprise Value | $83.55B | $19.93B |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
Hyatt Hotels Corp (H) trades at $177.71, down 0.65% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings beats in Q2 2026 and a raised RevPAR outlook highlight operational momentum, but high valuation ratios and a negative net income in 2025 pose concerns. The stock is near its 52-week high of $206.86, with support at $176 and resistance at $180.
The outlook is cautious; while fee growth and travel demand support expansion, the stock's rich valuation and debt levels warrant patience. Risks include regional weakness and project delays. Analysts maintain a mixed consensus with a $201 price target, suggesting limited near-term upside amid balanced investor sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
